Benefit of primary and secondary prophylactic implantable cardioverter defibrillator in elderly patients

被引:5
|
作者
Lewenhardt, Marie [1 ]
Kreimer, Fabienne [1 ]
Aweimer, Assem [2 ]
Pflaumbaum, Andreas [1 ]
Muegge, Andreas [1 ]
Gotzmann, Michael [1 ,3 ]
机构
[1] Ruhr Univ, Cardiol & Rhythmol, Univ Hosp St Josef Hosp Bochum, Gudrunstr 56, D-44791 Bochum, Germany
[2] Ruhr Univ, Univ Hosp Bergmannsheil Bochum, Cardiol, Bochum, Germany
[3] Ruhr Univ Bochum, Univ Hosp St Josef Hosp Bochum, Cardiol & Rhythmol, Gudrunstr 56, D-44791 Bochum, Germany
关键词
appropriate ICD therapy; benefit; elderly patients; implantable cardioverter defibrillator; ANTIARRHYTHMIC-DRUG THERAPY; PRIMARY PREVENTION; MANAGEMENT; AGE;
D O I
10.1002/clc.24191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The benefit of implantable cardioverter-defibrillator (ICD) in elderly patients has been questioned. In the present study, we aimed to analyse the outcome of patients of different age groups with ICD implantation.Methods We included all patients who received an ICD in our hospital from 2011 to 2020. Primary endpoints were (1) death from any cause and (2) appropriate ICD therapy (antitachycardia pacing/shock). A "benefit of ICD implantation" was defined as appropriate ICD therapy before death from any cause/or survival. "No benefit of ICD implantation" was defined as death from any cause without prior appropriate ICD therapy.Results A total of 422 patients received an ICD (primary prophylaxis n = 323, secondary prophylaxis n = 99). At the time of implantation, 35 patients (8%) were >80 years and 106 patients were >75 years (25%). During the study period of 4.2 +/- 3 years, benefit of ICD occurred in 89 patients (21%) and no benefit in 84 patients (20%). In primary prevention, the proportion of patients who had a benefit from ICD implantation decreased with increasing age, and there were no patients who benefited from ICD therapy in the group of patients >80 years. In secondary prophylaxis, the proportion of patients with a benefit from ICD implantation ranged from 20% to 30% in all age groups.Conclusion Our study suggests that the indication of primary prophylactic ICD in elderly and very old patients should be critically assessed. On the other hand, no patient should be denied secondary prophylactic ICD implantation because of age.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Primary prevention implantable cardioverter-defibrillator implantation in elderly patients: is it justified to withhold treatment?
    van der Heijden, Aafke C.
    van Erven, Lieselot
    Schalij, Martin J.
    Borleffs, C. Jan Willem
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (07) : 787 - 789
  • [22] The implantable defibrillator in primary prevention in elderly patients
    Vetta, Francesco
    Vetta, Giampaolo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (10) : 790 - 800
  • [23] Workforce affiliation in primary and secondary prevention implantable cardioverter defibrillator patients: a nationwide Danish study
    Rosenkranz, Simone H.
    Wichmand, Charlotte H.
    Smedegaard, Laerke
    Moller, Sidsel
    Bjerre, Jenny
    Schou, Morten
    Torp-Pedersen, Christian
    Philbert, Berit T.
    Larroude, Charlotte
    Melchior, Thomas M.
    Nielsen, Jens C.
    Johansen, Jens B.
    Riahi, Sam
    Holmberg, Teresa
    Gislason, Gunnar
    Ruwald, Anne-Christine
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2023, 10 (04) : 314 - 325
  • [24] Significant Survival Benefit in 286 Elderly Primary Prevention Patients with Implantable Cardioverter Defibrillators
    McGrew, Frank A.
    Johnson, Eric E.
    Coppess, Mark A.
    Hamilton, Barbara
    Charlton, Sandra B.
    Sims, James J.
    Charlton, Thomas A.
    JOURNAL OF CARDIAC FAILURE, 2009, 15 (06) : S103 - S104
  • [25] Primary prevention implantable cardioverter-defibrillator treatment: how to identify patients most likely to benefit?
    Thijssen, Joep
    van Rees, Johannes B.
    Schalij, Martin J.
    Borleffs, C. Jan Willem
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (10) : 1197 - 1199
  • [26] Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study
    Pelli, Ari
    Junttila, M. Juhani
    Kentta, Tuomas, V
    Schlogl, Simon
    Zabel, Markus
    Malik, Marek
    Reichlin, Tobias
    Willems, Rik
    Vos, Marc A.
    Harden, Markus
    Friede, Tim
    Sticherling, Christian
    Huikuri, Heikki, V
    EUROPACE, 2022, 24 (05): : 774 - 783
  • [27] Predicting benefit for implantable cardioverter-defibrillator use
    Soliman, Elsayed Z.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 286 - 287
  • [28] Survival after primary prevention implantable cardioverter-defibrillator implantation in the elderly
    Fauchier, L.
    Marijon, E.
    Defaye, P.
    Sadoul, N.
    Gras, D.
    Klug, D.
    Piot, O.
    Deharo, J. C.
    Leclercq, C. H.
    Boveda, S.
    EUROPEAN HEART JOURNAL, 2014, 35 : 768 - 768
  • [29] How to consider the indication of implantable cardioverter-defibrillator in the elderly patients
    Kataoka, Naoya
    Imamura, Teruhiko
    CLINICAL CARDIOLOGY, 2024, 47 (02)
  • [30] Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain
    van Rees, Johannes B.
    Borleffs, C. Jan Willem
    Thijssen, Joep
    de Bie, Mihaly K.
    van Erven, Lieselot
    Cannegieter, Suzanne C.
    Bax, Jeroen J.
    Schalij, Martin J.
    EUROPACE, 2012, 14 (01): : 66 - 73